Intravitreal injections are a very common procedure, performed approximately 6 million times a year in America. That number continues to grow as indications for anti-VEGF therapy increase and the population ages.
Read MoreCRVO is a frequently encountered retinal disease. Risk factors include age, glaucoma, or vascular diseases including hypertension, hyperlipidemia, and diabetes. Furthermore, smoking and taking oral contraceptives increase the risk in otherwise healthy individuals.
Read MoreBRVO is a disease of retinal circulation which may affect a patient’s vision. Macular ischemia, edema, vitreous hemorrhage, or neovascular glaucoma all may occur. The disease is more common with increasing age and in patients with hypertension, diabetes, or hypercholesterolemia.
Read MoreIn recent years, anti-VEGF injections have been utilized to treat patients with diabetic macular edema. While treating diabetics for edema with anti-VEGF therapy, an improvement in the diabetic retinopathy is frequently observed.
Read MoreThe treatment for diabetic retinopathy has come a long way in the past forty years. Initially an untreatable, blinding disease, it is now quite responsive to therapy.
Read MoreMacular degeneration is a common disease in America’s aging population. While dry AMD is more common, wet AMD is associated with greater risk for vision loss.
Read More